Patients with EGFR-mutant non-small cell lung cancer who are TKI-naïve benefited from receiving the Cyramza-Tagrisso combination versus Tagrisso alone.

Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials ...